A man who claimed that he developed severe bowel problems from Accutane
, an acne medication, has reached a pre-trial settlement with Roche Laboratories, the drugâ€™s manufacturer.
Roche has asked Madison County Circuit Judge David Hylla to approve the Accutane settlement, according to a report in The Madison Record
. The case, which was brought by plaintiff Jason Peipert, also involves a medical malpractice claim against an Illinois doctor, who may also be in settlement talks with the plaintiff.
Peipert alleges that Dr. Daniel Goran prescribed him Accutane to treat his acne, and that the drug caused him to develop the debilitating condition, inflammatory bowel disease (IBD). The case was set to go to trial on April 19, but start of the trial was delayed due the potential settlement with Accutane manufacturers.
Roche faces nearly 1,000 Accutane lawsuits
, which involve allegations that the drug maker failed to adequately warn users about potential side effects of Accutane. The company has lost all six Accutane bowel disease trials that have reached a jury so far, with verdicts totalling $56 million.
The largest judgment so far was awarded to Andrew McCarrell, of Alambama, who received $25.16 million in compensation by a New Jersey jury in an Accutane trial
earlier this year.
Details of the Accutane lawsuit settlement with Peipert have not been disclosed. However, the terms of the agreement do not include an admission of guilt from Roche, and Peipert has reportedly agreed not to bring another case against Roche in the future.
Accutane (isotretinoin) has been used by more than 16 million people worldwide since it was first introduced in the early 1980s as a treatment for severe acne. Roche discontinued the drug in June 2009, citing cost of defending Accutane suits as a factor in their decision. However, the acne medication remains available as a generic sold under a variety of names, such as Claravis, Sotret, Amnesteem and generic isotretinoin.